Effect of Hyoscine- Bromide on Duration of the First Stage of Labor

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06056869

Enrollment

Registered

2023-09-28

Start date

2023-09-27

Completion date

2024-04-30

Last updated

2023-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor

Brief summary

Spasmolytic drugs are frequently used in delivery rooms to overcome cervical spasms and thus reduce the duration of labor. The aim of this randomized double blind placebo controlled trial is to study the efficacy of hyoscine butylbromide (HBB) for shortening of the first stage of labor in primigravid women.

Interventions

DRUGhyoscine butylbromide

will be given during first stage of labor intravenously

OTHERnormal saline

placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

1. Primigravid women. 2. Singleton pregnancy. 3. Presenting by the vertex. 4. Gestational age between 37 and 42 weeks 5. In active phase of labor with a cervical dilatation between 4-5 cm, with either intact membranes or spontaneous rupture of membranes for less than 12 h

Exclusion criteria

1. Previous uterine scarring. 2. Malpresentation. 3. Antepartum hemorrhage. 4. Labor induction 5. Contraindication to vaginal delivery. 6. Contraindication to hyoscine.

Design outcomes

Primary

Measure	Time frame	Description
duration of first stage of labor	6 months	duration

Countries

Egypt

Contacts

Primary ContactMaii Nawara, MD

maii_nawara@hotmail.com+201001848388

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026